Kindred is an early stage venture capital firm that backed Lottie in its seed round.
Kindred Capital led the seed round to support international expansion and product development at m3ter.
"Usage-based pricing offers huge rewards for SaaS businesses, but it isn’t easy to implement. We experienced the pain ourselves when building our previous startup, but we also saw what good tooling can look like at AWS. Today, we’re proud to launch m3ter so that all SaaS businesses can intelligently deploy and manage usage-based pricing."
Gradient Ventures led the round with participation from Illuminate Financial, Kindred Capital, and Angular Ventures.
"Since announcing our platform to the market, the response has been remarkable,"
The revenue delivery platform has secured £52m in a Series C round led by FTV Capital to fuel global expansion.
"We are witnessing a systemic shift within software, with the ‘growth at any cost’ mindset gradually being replaced by a realisation that businesses must scale more efficiently and with clearer purpose. We’ve been extremely impressed with Christian and Harrison’s ambition and Paddle’s growth to date and we believe they are defining a new category with Paddle’s Revenue Delivery Platform — one that will be critical to helping companies adapt to change while empowering them to take advantage of the huge acceleration in demand for digital products. With more than two decades investing in the SaaS and payments sectors, FTV will bring the best of our domain expertise to accelerate Paddle’s exciting growth."
The funding round was led by Atomico with participation from Lux Capital, Obvious Ventures, Kindred Capital and Inovia Capital.
"To add a fund of Atomico’s calibre and reputation to our investor base is a huge win for LabGenius. Atomico’s operational experience is second to none and they are the perfect partner to help us scale a global company from Europe. In addition, the confidence that Lux, Obvious, Kindred and Inovia have demonstrated in doubling down in this round reflects the tremendous technical progress that the team has made over the past 12 months."
The Series A round was led by Northpond Ventures and Octopus Ventures to help bring the company manufacturing platform to market.
"Closing a significant Series A round, during these uncertain times, further validates Ori’s disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs,"
